American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

VERACYTE, INC.

$47.27 -3.00% NASDAQ: VCYT · 15-min delayed

SOUTH SAN FRANCISCO, California
Public · NASDAQ: VCYT
755 employees

Visit website Follow

$3.9BMarket cap

$517.1MRevenue · FY2025

$66.4MNet income

755Employees

VCYTNASDAQ

2013IPO

About VERACYTE, INC.

Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Type: Public · NASDAQ: VCYT
Employees: 755
IPO date: Oct 30, 2013
Headquarters: 6000 SHORELINE COURT, SUITE 300
SOUTH SAN FRANCISCO, California 94080
Phone: (650) 243-6300
Industry: Medical Devices
Website: Visit site

Registry IDs

Ticker: VCYT Nasdaq
SEC CIK: 1384101
LEI: 529900ESWZRHXOW27Z37
EIN: 205455398
SIC: 8071 SERVICES-MEDICAL LABORATORIES

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow VERACYTE, INC. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $517.1M
Net income: $66.4M
Total assets: $1.4B
Market cap: $3.9B
Gross margin: 70.1%
Operating margin: 11.2%
Net margin: 12.8%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

FY2020

FY2021

FY2022

FY2023

FY2025

Revenue Net income

FY 2025

Financial statements

Income statement

Revenue: $517.1M
Cost of revenue: $154.6M
Gross profit: $362.5M
Operating expenses: $304.8M
Operating income: $57.8M
Income tax: $1.8M
Net income: $66.4M
EPS (basic): $0.84
EPS (diluted): $0.82

Balance sheet

Total assets: $1.4B
Current assets: $488.4M
Total liabilities: $96.4M
Current liabilities: $59.9M
Shareholders’ equity: $1.3B

Cash flow

Operating cash flow: $136.3M
Investing cash flow: -$9.2M
Financing cash flow: -$4.2M
Net cash flow: $123.6M

Statements via Polygon.io (SEC filings)

NASDAQ: VCYT

$47.27 -3.00%

15-minute delayed · data by Polygon.io

Past year

$23.03 $49.94

52-week range

Market cap: $3.9B
P/E ratio: 57.6
EPS (diluted): $0.82
Shares outstanding: 82.3M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Oct 30, 2013

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

Profitable — net income of $66.4M in FY2025.
Revenue grew 340% from FY2020 to FY2025.
Gross margin of 70.1%, net margin 12.8%.
Trading 5% below its 52-week high.
Valued at a price-to-earnings (P/E) ratio of 57.6.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.